Transcode Therapeutics, Inc.

TransCode Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology and RNA therapeutics to treat advanced and metastatic cancers. The company's lead candidate, TTX-MC138, is designed to target microRNA-10b in metastatic tumor cells using an iron oxide nanoparticle delivery platform and is currently in Phase 2a clinical trials for multiple cancer types including breast, pancreatic, and ovarian cancer.